This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18:1609–1678
January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: A report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 64:2245–2280. https://doi.org/10.1016/j.jacc.2014.03.021
Chugh SS, Roth GA, Gillum RF, Mensah GA (2014) Global burden of atrial fibrillation in developed and developing nations. Glob Heart 9:113–119. https://doi.org/10.1016/j.gheart.2014.01.004
Krijthe BP, Kunst A, Benjamin EJ et al (2013) Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 34:2746–2751. https://doi.org/10.1093/eurheartj/eht280
Healey JS, Alings M, Ha A et al (2017) Subclinical atrial fibrillation in older patients. Circulation 136:1276–1283. https://doi.org/10.1161/CIRCULATIONAHA.117.028845
Ferro D, Loffredo L, Polimeni L, Violi F (2007) Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Intern Emerg Med 2:24–28. https://doi.org/10.1007/s11739-007-0005-2
Ogilvie IM, Newton N, Welner SA et al (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123:638.e4–645.e4. https://doi.org/10.1016/J.AMJMED.2009.11.025
Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891. https://doi.org/10.1056/NEJMoa1009638
Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962. https://doi.org/10.1016/S0140-6736(13)62343-0
Larsen TB, Skjøth F, Nielsen PB et al (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189. https://doi.org/10.1136/BMJ.I3189
Prisco D, Ageno W, Becattini C et al (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12:387–406. https://doi.org/10.1007/s11739-017-1628-6
Borghi C, Paolillo S, Cicero AFG et al (2017) New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation. J Hypertens 35:689–695. https://doi.org/10.1097/HJH.0000000000001228
Hsu JC, Maddox TM, Kennedy KF et al (2016) Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk. JAMA Cardiol 1:55. https://doi.org/10.1001/jamacardio.2015.0374
Kjerpeseth LJ, Ellekjær H, Selmer R et al (2017) Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol 73:1417–1425. https://doi.org/10.1007/s00228-017-2296-1
Gülker J-E, Kröger K, Kowall B et al (2018) Increasing use of anticoagulants in Germany and its impact on hospitalization for intracranial bleeding. Circ Cardiovasc Qual Outcomes 11:e004470. https://doi.org/10.1161/CIRCOUTCOMES.117.004470
Volterrani M, Iellamo F, Alberto C et al (2018) NOAC in “real world” patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. 2 Intern Emerg Med. https://doi.org/10.1007/s11739-018-1896-9 (in press)
Huisman MV, Rothman KJ, Paquette M et al (2017) The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol 69:777–785. https://doi.org/10.1016/j.jacc.2016.11.061
The authors report no specific funding in relation to the preparation of this paper.
Conflict of interest
The author(s) declare that they have no conflict of interest.
Statement of human and animal rights
This article does not contain any studies with human participants or animal performed by any of the authors.
No informed consent is required.
About this article
Cite this article
Mulè’, G., Carollo, C., Guarneri, M. et al. The changing landscape of thromboprophylaxis for atrial fibrillation: insights from the ISPAF-2 survey. Intern Emerg Med 13, 1005–1007 (2018). https://doi.org/10.1007/s11739-018-1929-4
- Landscape Change
- Non-valvular Atrial Fibrillation (NVAF)
- Norwegian Prescription Database
- Prolonged Electrocardiographic Monitoring